<DOC>
	<DOCNO>NCT02079649</DOCNO>
	<brief_summary>The purpose study evaluate two investigational ophthalmic solution reduction ocular redness subject allergic conjunctivitis .</brief_summary>
	<brief_title>Safety Efficacy Study AL-53817 AL-78843 Ophthalmic Solutions Allergic Conjunctivitis</brief_title>
	<detailed_description>Eligible subject attend 8 study visit , 5 include 3-hour period ragweed exposure Environmental Exposure Chamber . At sixth visit , subject receive study product begin dose 9 day . The final visit final day dose . Participation study last 68 day .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Sign Informed Consent Use condom sexually active male entire duration study . Best correct visual acuity 55 great eye measure ETDRS ( letter read method ) . Able willing comply study protocol follow protocol instruction . Able avoid topical ocular systemic exclude medication entire study period . At least 1 year subjectreported physiciandiagnosed history ( prior Screen Visit ) allergic conjunctivitis ragweed season . Positive skin prick test short ragweed allergen within 12 month prior Screen Visit . Significant staffassessed ocular redness least one region eye within 3 hour period allergen exposure EEC ( Screen Visits ) . Other protocoldefined inclusion criterion may apply . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose least 1 week follow last dose investigational product . Presence ocular infection , history ocular Herpes ( simplex zoster ) adenoviral infection either eye . History ocular infection , physician subject diagnose , within 30 day prior Screen Visit . Presence glaucoma , past history , diagnosis glaucoma ocular hypertension . Presence blepharitis , active rosacea affect ocular adnexa , meibomian gland dysfunction , follicular conjunctivitis , intraocular inflammation , preauricular lymphadenopathy ophthalmic abnormality may affect study outcome . Corneal condition affect corneal structure . Unwilling discontinue contact lens wear study period . Any ocular surgery include ocular laser procedure within 1 year prior Screen Visit . Current recent ( &lt; 6 month prior Screen Visit ) history severe , unstable , uncontrolled autoimmune , neurological , cardiovascular , hematological , hepatic , renal , psychological , respiratory , gastrointestinal and/or immunological disease evidence disease base upon review medical history and/or physical examination , opinion Investigator , would preclude safe subject participation study . Receiving treatment anxiety and/or depression Screen Visit ; history suicide attempt . Participation investigational study within 30 day Screen Visit concomitantly study . Known contraindication hypersensitivity study medication component Confirmed ( physician optometrist ) diagnosis dry eye . History sensitivity adverse reaction steroid . Known allergic reaction unresponsive corticosteroid nonsteroidal antiinflammatory drug ( NSAIDS ) . Physician diagnose asthma ( except inactive childhood asthma exerciseinduced asthma ) . Evidence active inflammation eye determine dilated fundus examination conduct Screen C Visit . Any corneal swelling haze determine slitlamp examination conduct Screen C Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Allergic conjunctivitis</keyword>
	<keyword>Red eye</keyword>
	<keyword>Eyelid swell</keyword>
	<keyword>Ragweed</keyword>
	<keyword>Allergies</keyword>
	<keyword>Itchy eye</keyword>
	<keyword>Ocular redness</keyword>
	<keyword>Chemosis</keyword>
	<keyword>Tearing</keyword>
	<keyword>Watery eye</keyword>
</DOC>